Baidu
map

新制剂使神经退行性疾病治疗获得突出进展!

2017-07-18 佚名 medicalxpress 

研究人员已经发现,帕金森病和阿尔茨海默氏病患者的死亡后脑中细胞受体异常过度表达,动物模型中可以抑制细胞受体,以清除毒性蛋白质积聚,减少脑部炎症,提高认知功能。

研究人员已经发现,帕金森病和阿尔茨海默氏病患者的死亡后脑中细胞受体异常过度表达,动物模型中可以抑制细胞受体,以清除毒性蛋白质积聚,减少脑部炎症,提高认知功能。

乔治城大学医学中心(GUMC)研究人员在伦敦阿尔茨海默病协会国际会议上提出的这些双重发现标志着受体(discoindin结构域受体(DDRs))首次被理解为在帕金森病和阿尔茨海默病中发挥作用。 (它们主要被认为是抗癌的潜在目标。)

研究的资深作者,神经科学家Charbel Moussa,MBBS说:“这些细胞受体的活化似乎阻止脑细胞清除垃圾 - 蛋白质的毒性积累,如α-突触核蛋白,tau和淀粉样蛋白,常见于神经变性疾病。

过量的DDRs激活可能会关闭自噬,导致脑细胞内毒性蛋白质的积累,并可能导致神经退行性疾病中常见的血脑屏障破裂。

酪氨酸激酶抑制剂的DDRs抑制剂似乎通过血脑屏障修复使大脑绝缘,这可以防止在体内循环的有害免疫细胞进入大脑,在那里他们可以不加区别地攻击和杀死健康和病态的神经元,如那些无法进行自噬的神经元。

神经学副教授Moussa解释说:“我们研究了进入大脑并抑制DDRs的实验性酪氨酸激酶抑制剂。 “使用低剂量的药物LCB-03-110抑制这些受体,或者在帕金森病和阿尔茨海默氏病的几种模型中减少DDRs表达使得神经细胞能够开启自噬以清除有毒的蛋白质,这导致我们的动物模型的认知改善。

Moussa已经发现了其他针对自噬过程的药剂。用于治疗白血病的一种此类药物尼罗替尼(诺华公司的Tasigna)正在帕金森病和阿尔茨海默病患者中进行研究。

乔治敦已经提交了与使用某些DDR抑制剂相关的专利申请来治疗神经变性疾病。穆萨是保护知识产权的命名发明家。此外,乔治敦州还持有美国有关技术的美国专利,用于使用尼罗替尼治疗某些神经退行性疾病,并在美国和外国司法部门拥有其他待批专利申请。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1982770, encodeId=a9151982e7014, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Aug 24 09:16:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957148, encodeId=b527195e1484e, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Sat Feb 10 23:16:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735375, encodeId=7c6c1e35375f1, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Wed Apr 25 05:16:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223888, encodeId=1c3322388842, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jul 19 11:37:43 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223867, encodeId=924622386e9e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Wed Jul 19 10:25:11 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223678, encodeId=5e042236e83b, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Jul 18 23:33:19 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223619, encodeId=b1412236192d, content=新研究有望突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C3426ED027FF661B0C576A5B3127C2E8/40, createdBy=39dc1706090, createdName=QQ25ed180f, createdTime=Tue Jul 18 19:10:09 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1982770, encodeId=a9151982e7014, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Aug 24 09:16:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957148, encodeId=b527195e1484e, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Sat Feb 10 23:16:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735375, encodeId=7c6c1e35375f1, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Wed Apr 25 05:16:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223888, encodeId=1c3322388842, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jul 19 11:37:43 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223867, encodeId=924622386e9e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Wed Jul 19 10:25:11 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223678, encodeId=5e042236e83b, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Jul 18 23:33:19 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223619, encodeId=b1412236192d, content=新研究有望突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C3426ED027FF661B0C576A5B3127C2E8/40, createdBy=39dc1706090, createdName=QQ25ed180f, createdTime=Tue Jul 18 19:10:09 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1982770, encodeId=a9151982e7014, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Aug 24 09:16:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957148, encodeId=b527195e1484e, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Sat Feb 10 23:16:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735375, encodeId=7c6c1e35375f1, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Wed Apr 25 05:16:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223888, encodeId=1c3322388842, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jul 19 11:37:43 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223867, encodeId=924622386e9e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Wed Jul 19 10:25:11 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223678, encodeId=5e042236e83b, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Jul 18 23:33:19 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223619, encodeId=b1412236192d, content=新研究有望突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C3426ED027FF661B0C576A5B3127C2E8/40, createdBy=39dc1706090, createdName=QQ25ed180f, createdTime=Tue Jul 18 19:10:09 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1982770, encodeId=a9151982e7014, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Aug 24 09:16:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957148, encodeId=b527195e1484e, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Sat Feb 10 23:16:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735375, encodeId=7c6c1e35375f1, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Wed Apr 25 05:16:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223888, encodeId=1c3322388842, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jul 19 11:37:43 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223867, encodeId=924622386e9e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Wed Jul 19 10:25:11 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223678, encodeId=5e042236e83b, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Jul 18 23:33:19 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223619, encodeId=b1412236192d, content=新研究有望突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C3426ED027FF661B0C576A5B3127C2E8/40, createdBy=39dc1706090, createdName=QQ25ed180f, createdTime=Tue Jul 18 19:10:09 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
    2017-07-19 李东泽

    很好,不错,以后会多学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1982770, encodeId=a9151982e7014, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Aug 24 09:16:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957148, encodeId=b527195e1484e, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Sat Feb 10 23:16:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735375, encodeId=7c6c1e35375f1, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Wed Apr 25 05:16:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223888, encodeId=1c3322388842, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jul 19 11:37:43 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223867, encodeId=924622386e9e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Wed Jul 19 10:25:11 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223678, encodeId=5e042236e83b, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Jul 18 23:33:19 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223619, encodeId=b1412236192d, content=新研究有望突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C3426ED027FF661B0C576A5B3127C2E8/40, createdBy=39dc1706090, createdName=QQ25ed180f, createdTime=Tue Jul 18 19:10:09 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
    2017-07-19 海棠胜雪

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1982770, encodeId=a9151982e7014, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Aug 24 09:16:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957148, encodeId=b527195e1484e, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Sat Feb 10 23:16:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735375, encodeId=7c6c1e35375f1, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Wed Apr 25 05:16:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223888, encodeId=1c3322388842, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jul 19 11:37:43 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223867, encodeId=924622386e9e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Wed Jul 19 10:25:11 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223678, encodeId=5e042236e83b, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Jul 18 23:33:19 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223619, encodeId=b1412236192d, content=新研究有望突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C3426ED027FF661B0C576A5B3127C2E8/40, createdBy=39dc1706090, createdName=QQ25ed180f, createdTime=Tue Jul 18 19:10:09 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
    2017-07-18 坚强007

    期待

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1982770, encodeId=a9151982e7014, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Aug 24 09:16:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957148, encodeId=b527195e1484e, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Sat Feb 10 23:16:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735375, encodeId=7c6c1e35375f1, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Wed Apr 25 05:16:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223888, encodeId=1c3322388842, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jul 19 11:37:43 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223867, encodeId=924622386e9e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Wed Jul 19 10:25:11 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223678, encodeId=5e042236e83b, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Jul 18 23:33:19 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223619, encodeId=b1412236192d, content=新研究有望突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C3426ED027FF661B0C576A5B3127C2E8/40, createdBy=39dc1706090, createdName=QQ25ed180f, createdTime=Tue Jul 18 19:10:09 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
    2017-07-18 QQ25ed180f

    新研究有望突破

    0

相关资讯

药监局修订雷公藤中成药说明书

  为控制药品使用风险,近日,国家食品药品监督管理局根据药品不良反应评估结果,对雷公藤中成药制剂的说明书进行了修订。   修订后的要求   一、增加警示语,内容如下:   警示语:雷公藤制剂不良反应可涉及多系统损害,应严格按说明书在医师指导下使用。   二、【不良反应】项应当包括:   1.消化系统:口干、恶心、呕吐、乏力、食欲不振、腹胀、腹泻、黄疸、转氨酶升高;严重者可出现急性中毒性肝

药物制剂常用设备名称中英文

药物制剂常用设备名称中英文 粉碎 粗粉碎机 Rough pulverizer 万能粉碎机 Universal pulverizer 高效粉碎机 High-efficient pulverizer 微粉碎机 Micro-particle pulverizer 超微(气流)粉碎机 Super-micro-particle(air flow)pulverizer 低温粉碎机 Low temperatur

Baidu
map
Baidu
map
Baidu
map